Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial Active — Not Recruiting NCT05005949

STOP Persistent AF PAS

STOP Persistent AF PAS — Active Not Recruiting • Cardiology / Cardiovascular • NCT05005949.

📅 22 Jul 2026 ⏱ 1 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
NCT ID
NCT05005949
Start
2021-08-19
Completion
2028-07
ClinicaliQ Trial Snapshot
  • STOP Persistent AF PAS — Active Not Recruiting • Cardiology / Cardiovascular • NCT05005949.
  • STOP Persistent AF Post Approval Study.
  • A worldwide study tracking real-world outcomes in patients receiving treatment for persistent atrial fibrillation outside controlled trial settings.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The STOP Persistent AF Post Approval Study (PAS) is a prospective, global, multicenter, observational trial. Conditions: Persistent Atrial Fibrillation Interventions: Arctic Front™ Cardiac Cryoablation Catheter System Lead Sponsor: Medtronic Cardiac Ablation Solutions Planned Enrollment: 400 participants

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
2024 ESC Guidelines for the Management of Atrial Fibrillation
Cardiology / Cardiovascular · 30 Mar 2026
Covers AF classification, stroke risk assessment (CHA2DS2-VASc), and bleeding risk (HAS-BLED) • Provides recommendations for rate vs rhythm control strategies • Addresses…
View guideline →
Clinical Brief
How Eriksen’s heart device kicked into action
Cardiology / Cardiovascular · BBC Health · 08 Jun 2026
Christian Eriksen's implanted cardioverter-defibrillator (ICD) functioned appropriately during his on-pitch cardiac arrest, demonstrating effective device intervention in a real-world emergency scenario The…
View brief →
Guideline
Finerenone for treating chronic heart failure with preserved or mildly reduced ejection fraction
Cardiology / Cardiovascular · 05 Aug 2026
Finerenone is recommended as an option for chronic heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) and can be initiated…
View guideline →
Clinical Brief
What in the World
Cardiology / Cardiovascular · BBC Health · 07 Jul 2026
Heatwaves pose significant clinical risk, with heatstroke and dehydration representing the primary acute complications requiring recognition and management Healthcare professionals should anticipate…
View brief →
Guideline
Sotatercept for treating pulmonary arterial hypertension
Cardiology / Cardiovascular · 03 Jun 2026
Sotatercept is recommended as a treatment option for pulmonary arterial hypertension (PAH) in patients who meet NICE criteria; verify patient eligibility and…
View guideline →
Guideline
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Cardiology / Cardiovascular · 07 May 2026
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part…
View guideline →